These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 2629126

  • 1. [Effect of treatment with recombinant interferon alfa on natural killer activity in patients with chronic type B lymphatic leukemia].
    Villamor N, Montserrat E, Urbano-Ispízua A, Ribera JM, Rovira M, Vives Corrons JL, Rozman C.
    Sangre (Barc); 1989 Dec; 34(6):485-8. PubMed ID: 2629126
    [Abstract] [Full Text] [Related]

  • 2. Effect of recombinant alpha-interferon administration on peripheral blood lymphocyte subpopulations and natural killer cell activity in patients with refractory anemia with excess of blasts.
    Eliopoulos G, Coulocheri S, Vaiopoulos G, Alexandrakis M, Ganotakis E, Eliopoulos A, Yataganas X.
    Nouv Rev Fr Hematol (1978); 1991 Dec; 33(1):21-4. PubMed ID: 1945821
    [Abstract] [Full Text] [Related]

  • 3. Recombinant alpha-2b-interferon may restore natural-killer activity in patients with B-chronic lymphocytic leukemia.
    Villamor N, Reverter JC, Montserrat E, Urbano-Ispízua A, Vives-Corrons JL, Rozman C.
    Leukemia; 1992 Jun; 6(6):547-52. PubMed ID: 1376376
    [Abstract] [Full Text] [Related]

  • 4. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
    O'Brien S, Kantarjian H, Beran M, Robertson LE, Koller C, Lerner S, Keating MJ.
    Blood; 1995 Aug 15; 86(4):1298-300. PubMed ID: 7632936
    [Abstract] [Full Text] [Related]

  • 5. CD4, CD8 and NK subsets in B-CLL.
    Vuillier F, Tortevoye P, Binet JL, Dighiero G.
    Nouv Rev Fr Hematol (1978); 1988 Aug 15; 30(5-6):331-4. PubMed ID: 3265505
    [Abstract] [Full Text] [Related]

  • 6. Low-dose "natural" alpha-interferon in B-cell derived chronic lymphocytic leukemia.
    Pozzato G, Franzin F, Moretti M, Tulissi P, Pecorari P, Melato M, Zacchi T, Evangelisti P, Campanacci L.
    Haematologica; 1992 Aug 15; 77(5):413-7. PubMed ID: 1483591
    [Abstract] [Full Text] [Related]

  • 7. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
    Koren HS, Brandt CP, Tso CY, Laszlo J.
    J Biol Response Mod; 1983 Aug 15; 2(2):151-65. PubMed ID: 6644332
    [Abstract] [Full Text] [Related]

  • 8. Recombinant alpha-2a interferon in treatment of B-chronic lymphocytic leukemia. A preliminary report with emphasis on previously untreated patients in early stage of disease.
    Molica S, Alberti A.
    Haematologica; 1990 Aug 15; 75(1):75-8. PubMed ID: 2338291
    [Abstract] [Full Text] [Related]

  • 9. Production of intracellular IL-2, TNF-alpha, and IFN-gamma by T cells in B-CLL.
    Gallego A, Vargas JA, Castejón R, Citores MJ, Romero Y, Millán I, Durántez A.
    Cytometry B Clin Cytom; 2003 Nov 15; 56(1):23-9. PubMed ID: 14582134
    [Abstract] [Full Text] [Related]

  • 10. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
    Lotzová E, Savary CA, Quesada JR, Gutterman JU, Hersh EM.
    J Natl Cancer Inst; 1983 Nov 15; 71(5):903-10. PubMed ID: 6580490
    [Abstract] [Full Text] [Related]

  • 11. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
    Mauro FR, Zinzani P, Zaja F, Gentile M, Vegna ML, Stefoni V, Marin L, Fanin R, Baccarani M, Tura S, Mandelli F.
    Haematologica; 2003 Dec 15; 88(12):1348-57. PubMed ID: 14687987
    [Abstract] [Full Text] [Related]

  • 12. The effectors of killer activity induced by interferon-alpha and gamma in peripheral blood mononuclear cells.
    Sakaguchi M, Kubota S, Nishikido M, Taniguchi K, Inuzuka S, Saito Y, Kanetake H, Koga S.
    Int J Mol Med; 2002 Sep 15; 10(3):317-20. PubMed ID: 12165807
    [Abstract] [Full Text] [Related]

  • 13. [A study of effective administration of recombinant interferon-gamma in renal cell carcinoma regarding immunological influence on peripheral blood lymphocytes].
    Kawata N, Ono M, Kodama M, Yamanaka Y, Hirakata H, Hirano D, Fuse T, Takimoto Y.
    Hinyokika Kiyo; 1995 Jan 15; 41(1):21-6. PubMed ID: 7900565
    [Abstract] [Full Text] [Related]

  • 14. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP, Baxevanis CN, Papadopoulos NG, Zarkadis IK, Papacostas P, Michailakis E, Tsiatas ML, Papamichail M.
    Anticancer Res; 1996 Jan 15; 16(6B):3855-60. PubMed ID: 9042270
    [Abstract] [Full Text] [Related]

  • 15. In vivo priming effects of interferon-beta ser on NK activity of peripheral blood mononuclear cells in cancer patients.
    Fujimiya Y, Wagner RJ, Groveman S, Sielaff K, Kohsaka T, Nakayama M.
    Ther Immunol; 1995 Feb 15; 2(1):15-22. PubMed ID: 7553067
    [Abstract] [Full Text] [Related]

  • 16. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H, Gavigan M, O'Malley J, Thompson D, Dadey B, Nussbaum-Blumenson A, Snider C, Rudnick S, Ferraresi R, Norred S.
    J Biol Response Mod; 1983 Feb 15; 2(6):499-515. PubMed ID: 6607323
    [Abstract] [Full Text] [Related]

  • 17. The expression of NK cell inhibitory receptors on cytotoxic T cells in B-cell chronic lymphocytic leukaemia (B-CLL).
    Junevik K, Werlenius O, Hasselblom S, Jacobsson S, Nilsson-Ehle H, Andersson PO.
    Ann Hematol; 2007 Feb 15; 86(2):89-94. PubMed ID: 17043777
    [Abstract] [Full Text] [Related]

  • 18. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.
    Gitelson E, Hammond C, Mena J, Lorenzo M, Buckstein R, Berinstein NL, Imrie K, Spaner DE.
    Clin Cancer Res; 2003 May 15; 9(5):1656-65. PubMed ID: 12738718
    [Abstract] [Full Text] [Related]

  • 19. Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia.
    Sacchi S, Cortes J, Kantarjian H, Talpaz M.
    Hematopathol Mol Hematol; 2003 May 15; 11(1):41-7. PubMed ID: 9439979
    [Abstract] [Full Text] [Related]

  • 20. Defective NK cell activity following thermal injury.
    Klimpel GR, Herndon DN, Fons M, Albrecht T, Asuncion MT, Chin R, Stein MD.
    Clin Exp Immunol; 1986 Nov 15; 66(2):384-92. PubMed ID: 3493101
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.